Oregon Public Employees Retirement Fund’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Oregon Public Employees Retirement Fund’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-33,943	Closed	-$129K	–	1622
2020 Q1	$129K	Hold	33,943	–	–	﹤0.01%	1440
2019 Q4	$173K	Hold	33,943	–	–	﹤0.01%	1495
2019 Q3	$172K	Buy	33,943 +600	+2%	+$2.99K	﹤0.01%	1538
2019 Q2	$206K	Buy	33,343 +600	+2%	+$2.89K	﹤0.01%	1530
2019 Q1	$152K	Buy	32,743 +591	+2%	+$2.67K	﹤0.01%	1564
2018 Q4	$135K	Buy	+32,152	New	+$164K	﹤0.01%	1586

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Oregon Public Employees Retirement Fund's PGNX Position: Q2 2020 in Review

Oregon Public Employees Retirement Fund sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 33,943 shares — an estimated $129K sold.

Oregon Public Employees Retirement Fund first reported a position in PGNX in Q4 2018 and held it in 6 quarters. The position peaked at $206K in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Oregon Public Employees Retirement Fund reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Oregon Public Employees Retirement Fund sold 33,943 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $129K.
Oregon Public Employees Retirement Fund first reported a position in Progenics Pharmaceuticals Inc in Q4 2018 and held it in 6 quarters.
Oregon Public Employees Retirement Fund's Progenics Pharmaceuticals Inc position peaked at $206K in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Oregon Public Employees Retirement Fund's 13F filing for Q2 2020, filed 21 Jul 2020.